A one-arm,single center study on the efficacy and safety of Iparomlimab/Tuvonralimab (PD-1/CTLA-4 bispecific antibody) in combination with platinum-containing chemotherapy and bevacizumab in the treatment of persistent, recurrent cervical cancer after pelvic excision

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: b54a07f64e20be75654c239a1f801ba570c9f6b4
First added on: Oct 10, 2026